首页|益肾补脾汤治疗糖尿病肾病Ⅳ期的疗效观察

益肾补脾汤治疗糖尿病肾病Ⅳ期的疗效观察

扫码查看
目的 研究并探讨益肾补脾汤治疗糖尿病肾病Ⅳ期的疗效.方法 50 例糖尿病肾病Ⅳ期患者,按随机数字表法分为对照组和研究组,每组 25 例.对照组应用常规西医治疗方案,研究组在对照组基础上应用益肾补脾汤治疗.对比两组血糖指标(空腹血糖、餐后 2 h血糖、糖化血红蛋白),肾功能指标(血肌酐、尿素氮、尿白蛋白肌酐比值、肾小球滤过率),生活质量,不良反应发生情况.结果 治疗后,两组空腹血糖、餐后 2 h血糖、糖化血红蛋白相比于治疗前均明显降低,且研究组的空腹血糖(5.45±0.83)mmol/L、餐后 2 h血糖(8.56±0.97)mmol/L、糖化血红蛋白(5.29±0.54)%均低于对照组的(6.95±0.92)mmol/L、(10.69±1.05)mmol/L、(6.03±0.67)%(P<0.05).治疗后,两组血肌酐、尿素氮、尿白蛋白肌酐比值相比于治疗前降低,肾小球滤过率相比于治疗前升高,且研究组中血肌酐(82.05±7.39)μmol/L、尿素氮(6.14±0.89)mmol/L、尿白蛋白肌酐比值(10.64±1.59)mg/mmol均低于对照组的(90.43±8.07)μmol/L、(7.03±0.97)mmol/L、(12.50±1.87)mg/mmol,肾小球滤过率(119.05±5.46)ml/min高于对照组的(113.24±5.07)ml/min(P<0.05).治疗后,两组生理、心理、环境、社会关系评分相比于治疗前均升高,且研究组生理评分(89.75±6.48)分、心理评分(89.07±6.02)分、环境评分(90.14±6.15)分、社会关系评分(89.96±6.27)分均高于对照组的(82.93±6.85)、(82.40±6.13)、(83.27±6.30)、(83.14±6.54)分(P<0.05).治疗后,两组不良反应发生率对比无明显差异(P>0.05).结论 在糖尿病肾病Ⅳ期患者治疗时,应用常规西医治疗方案联合益肾补脾汤治疗可增强疗效,更好地改善患者血糖水平和肾功能,且这种治疗方案应用后的不良反应少,安全性良好.
Observation on the curative effect of Yishen Bupi Decoction on stage Ⅳ diabetic kidney disease
Objective To study and explore the curative effect of Yishen Bupi Decoction on stage Ⅳ diabetic kidney disease.Methods 50 patients with stage Ⅳ diabetic kidney disease were divided into a control group and a study group according to random number table method,with 25 cases in each group.The control group was treated with conventional Western medicine,and the study group was treated with Yishen Bupi Decoction on the basis of the control group.Both groups were compared in terms of blood glucose indicators(fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin),renal function indicators(serum creatinine,urea nitrogen,urinary albumin to creatinine ratio,glomerular filtration rate),quality of life,and occurrence of adverse reactions.Results After treatment,the fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in both groups were significantly reduced compared with those before treatment;in the study group,the fasting blood glucose was(5.45±0.83)mmol/L,the 2 h postprandial blood glucose was(8.56±0.97)mmol/L and the glycosylated hemoglobin was(5.29±0.54)%,which were lower than(6.95±0.92)mmol/L,(10.69±1.05)mmol/L and(6.03±0.67)%in the control group(P<0.05).After treatment,the serum creatinine,urea nitrogen,urinary albumin to creatinine ratio in both groups were lower than those before treatment,and the glomerular filtration rate was higher than that before treatment;the study group had serum creatinine of(82.05±7.39)μmol/L,urea nitrogen of(6.14±0.89)mmol/L,urinary albumin to creatinine ratio of(10.64±1.59)mg/mmol,which were lower than(90.43±8.07)μmol/L,(7.03±0.97)mmol/L,(12.50±1.87)mg/mmol in the control group;the glomerular filtration rate of(119.05±5.46)ml/min in the study group was higher than(113.24±5.07)ml/min in the control group(P<0.05).After treatment,the physiological,psychological,environmental,and social relationship scores in both groups were increased compared with those before treatment;in the study group,the physiological score was(89.75±6.48)points,the psychological score was(89.07±6.02)points,the environmental score was(90.14±6.15)points,and the social relationship score was(89.96±6.27)points,which were higher than(82.93±6.85),(82.40±6.13),(83.27±6.30),and(83.14±6.54)points in the control group(P<0.05).After treatment,there was no significant difference in incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion In the treatment of patients with stage Ⅳ diabetic kidney disease,the application of conventional Western medicine regimen combined with Yishen Bupi Decoction can enhance the therapeutic efficacy and better improve the patients'blood glucose level and renal function,and the application of this treatment program has fewer adverse reactions and good safety.

Stage Ⅳ diabetic kidney diseaseIntegrated traditional Chinese and Western medicine therapyYishen Bupi DecoctionTraditional Chinese medicine

黄海健

展开 >

310000 杭州诚鸿医院

糖尿病肾病Ⅳ期 中西医结合疗法 益肾补脾汤 中药

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(18)